Phase 2 Kidney Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• Adults aged 18 or older of any gender
• People with advanced clear cell kidney cancer (a specific type of kidney cancer) confirmed by laboratory testing, where curative surgery is not possible
• People who have not yet received any systemic (whole-body) treatment for their advanced kidney cancer
• People whose doctors expect them to live for at least 3 more months
• People who are reasonably active and able to care for themselves, based on standard medical scoring tools (confirm with trial site)
• People who have at least one area of cancer that can be measured on scans, according to standard guidelines
• People whose blood, liver, and kidney test results fall within acceptable ranges set by the trial (confirm with trial site for specific values)
• People who are willing to sign a consent form and follow all study procedures

Who may not be able to join:

• People whose cancer has spread to the brain or central nervous system
• People who have previously received any anti-cancer treatment, including chemotherapy, biological therapy, immunotherapy, or certain traditional medicines with anti-cancer uses
• People who have had major surgery within 28 days before starting the trial and have not yet fully recovered, or who have curative kidney surgery planned during the study
• People who have had another type of cancer within the past 5 years, with some exceptions such as certain early-stage or cured skin, cervical, thyroid, or prostate cancers (confirm with trial site)
• People with significant digestive system problems that could affect how the body absorbs medication, such as inflammatory bowel disease, active stomach ulcers, or a recent history of bowel perforation or abdominal abscess within 28 days before starting
• People who need higher-dose steroid medications or other immune-suppressing drugs on an ongoing basis, unless used in specific limited ways such as skin creams, inhalers, or low-dose replacement therapy (confirm with trial site)
• People with significant heart or blood vessel problems in the past 6 months, such as a stroke, heart attack, unstable chest pain, heart failure, or serious irregular heartbeat, or people with certain abnormal heart test results before starting
• People who have had an organ transplant (other than a cornea transplant) or a bone marrow transplant from a donor
• People with active hepatitis B or C infection with detectable virus levels, known HIV infection, or active tuberculosis
• People with current or past lung inflammation conditions that are symptomatic or required steroid treatment
• People with serious ongoing infections requiring treatment, significant fluid build-up around the lungs or heart that needed draining in the past two weeks, a history of serious blood clotting or bleeding disorders, a significant bleeding event within the past month, or a history of severe psychiatric illness
• People who previously had severe immune-related side effects (grade 3–4) from earlier treatments (confirm with trial site)
• People with severe allergies or known hypersensitivity to any component of the study drug, including reactions to similar antibody-based medicines
• People who have taken part in another clinical trial and received an experimental treatment within 28 days before starting this trial
• People with significant organ problems or other serious health conditions likely to interfere with following the study plan
• People who have received a live vaccine within 30 days before starting, or who plan to receive one during the study or within one month after finishing
• Women who are pregnant or currently breastfeeding (women who agree to stop breastfeeding before signing the consent form may still be considered)
• People with any other condition that, in the treating doctor's judgement, makes participation unsuitable

Important: Always verify eligibility with the trial site directly before applying.